Meet The Team

Leadership

Neil Desai, PhD

Founder, CEO and President

SVP, Global R&D, Abraxis Bioscience; VP, Strategic Platforms, Celgene Corp;
Inventor of the nab® technology, Abraxane® and ABI-009. Successfully led
Abraxane team through all development stages. 20 + yrs experience. Strong
recognition in nanomedicine community. Board and advisory positions in
multiple start-ups.

Mitchall Clark, Bpharm, MRPharmS Regulatory Affairs and Quality

Chief Regulatory /Quality, Atara Biotherapeutics; SVP Regulatory Affairs,
Nantworks; SVP Regulatory affairs at Abraxis Bioscience; responsible for global
approvals for Abraxane®; regulatory for early stage to post-marketing of nab
products; 30+ yrs in international regulatory affairs with Schering AG, FH
Faulding/Purepac & APP/Abraxis. Clinical and manufacturing QA, drug safety
and clinical operations.

Berta Grigorian, BS

Clinical Operations

Clinical Operations Manager, Amgen Inc. 19+ years industry experience in all
phases of drug development, Oncology and Cardiovascular products. Led cross
functional teams management to plan and execute successful US BLA filing for
Amgen cardiovascular product; Led global activities for various oncology
studies to ensure quality, consistency, and integration of all study data;
Responsible for global study management goals (enrollment, data flow, drug
supply)

Advisors

Daniel D. Von Hoff, M.D., F.A.C.P. : Clinical Advisor

Mayo Clinic, TGen, US Oncology.

Physician in Chief, Distinguished Professor, Director of Clinical Translational
Research Division at TGen;

CSO, US Oncology Research;

Professor of Medicine, Mayo Clinic, Scottsdale, AZ.

Recognized expert in Oncology drug development;

PI on numerous phase I-III clinical trials including Abraxane; >620 papers, 137 book
chapters

2010 David A. Karnofsky Memorial Award from ASCO; Past President of the AACR;
Appointed to President Bush’s National Cancer Advisory Board in 2004-2010.

Founder of ILEX™ Oncology.

Sant Chawla, MD, FRACP : Advisor, Oncology Programs

Director, Sarcoma Oncology Center, Santa Monica, CA.

Academic appointments and affiliations: Stanford Univ Medical Center, MD
Anderson Cancer Center, David Geffen School of Medicine UCLA, Keck School of
Medicine USC, Cedars Sinai Medical Center

Extensive Clinical trial experience (>30 yrs) : Phase 1-3. Pazopanib, Denosumab,
Ridoforolimus (rapamycin analog), Palifosfomide, Aldoxorubicin, TH302,
belinostat, ofatumumab, AMG655, MEK162 and others

Mark Gladwin, MD : University of Pittsburgh School of Medicine [PAH]

Chief of the Pulmonary, Allergy and Critical Care Medicine Division

Recognized expert in pulmonary hypertension and sickle cell disease

PI, AADI Pulmonary Hypertension Phase I/II trial

> 200 publications

Investigator in > 25 clinical trials

Mahmood Razavi, MD : St Joseph Heart and Vascular Center [PAD]

Director, Center for Clinical Trials and Research, St Joseph, Orange, CA

Recognized expert in interventional cardiology, interventional radiology,
peripheral artery disease

Former Assoc Prof, acting Chief of Interventional Radiology, Stanford Univ

Investigator in > 45 clinical trials

Author of > 250 publications

Founder/Cofounder of 4 medical start-ups; Board and Advisory positions in Device
and Biotechnology companies

About Us- Clinical